Abstract:Abstract TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 protein oncogenic properties. The p53-targeted therapy approach began with the identification of compounds capable of restoring/reactivating wild-type p53 functions or eliminating mutant p53. Treatments that directly target mutant p53 are extremely structure and drug-species-dependent. Due to the mutation of wild-type p53, multiple survival pathways that are normally maintained by wild-type p53 are disrupted, necessitating the activation of compensatory genes or pathways to promote cancer cell survival. Additionally, because the oncogenic functions of mutant p53 contribute to cancer proliferation and metastasis, targeting the signaling pathways altered by p53 mutation appears to be an attractive strategy. Synthetic lethality implies that while disruption of either gene alone is permissible among two genes with synthetic lethal interactions, complete disruption of both genes results in cell death. Thus, rather than directly targeting p53, exploiting mutant p53 synthetic lethal genes may provide additional therapeutic benefits. Additionally, research progress on the functions of noncoding RNAs has made it clear that disrupting noncoding RNA networks has a favorable antitumor effect, supporting the hypothesis that targeting noncoding RNAs may have potential synthetic lethal effects in cancers with p53 mutations. The purpose of this review is to discuss treatments for cancers with mutant p53 that focus on directly targeting mutant p53, restoring wild-type functions, and exploiting synthetic lethal interactions with mutant p53. Additionally, the possibility of noncoding RNAs acting as synthetic lethal targets for mutant p53 will be discussed.

Crosslink between p53 and metastasis: focus on epithelial–mesenchymal transition, cancer stem cell, angiogenesis, autophagy, and anoikis

Functional Diversity of P53 in Human and Wild Animals

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe

Targeting mutant p53: a key player in breast cancer pathogenesis and beyond

Recent Advances on Mutant p53: Unveiling Novel Oncogenic Roles, Degradation Pathways, and Therapeutic Interventions

p53 and its mutants in tumor cell migration and invasion

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins

Targeting mutant p53 for cancer therapy: direct and indirect strategies

p53 signaling and autophagy in cancer: a revolutionary strategy could be developed for cancer treatment.

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

p53 signaling in cancer progression and therapy

Mutant p53 in Cancer Progression and Targeted Therapies

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Mutant P53 Drives Pancreatic Cancer Metastasis Through Cell-Autonomous PDGF Receptor Β Signaling

Mutant p53 as a guardian of the cancer cell

TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications

Targeting P53 for Novel Anticancer Therapy.

Mutant p53 in cancer therapy-the barrier or the path.